Pick the best.
This is Accelera, the Contract Research Organization (CRO) of choice as Drug Development Partner for pharmaceutical and biotechnology companies around the world.

We support all stages of drug discovery and development by offering integrated services, including Attrition Reducing Technologies (ART) and Toxicology Screening to help “pick the best” drug candidates, as well as Regulatory Drug Safety, Safety Pharmacology, ADME, Bioanalysis and Pharmacokinetic studies to translate and develop new chemical entities and biotherapeutics into novel medicines.

At Accelera sponsors and partners will find a unique platform of integrated scientific, technological and regulatory expertise, built on decades of experience in the international pharmaceutical industry.
Please contact us if you would like to learn how Accelera can help accomplish the challenges of your programs, request a quotation or just ask for more information about our services.

We would be pleased to arrange a visit by one of our representatives. Or better still, why not come to Milan and let us show you around the Accelera facilities?

We hope to hear from you soon.
ACCELERA INTEGRATED SERVICES

- Attrition Reducing Technologies (ART)
- Toxicology Screening
- IND enabling Packages
- Safety Pharmacology
- Chronic Toxicology
- Developmental and Reproductive Toxicology (DART)
- Clinical Bioanalysis & Pharmacokinetics
- PK/PD Modelling
- Translational Sciences
- Isotope Chemistry/Drug Disposition
- Metabolite Profiling and Identification
- Regulatory Consultancy & Documentation
EXPERIENCE

RESULTS:

ACCELERA
ONCOLOGY

Accelera provides support services and consultancy to develop both New Chemical Entities (NCEs) and biologics as new oncology drugs through Accelera Oncology, a dedicated team of experts in preclinical tumor models, PK/PD, Attrition Reducing Technologies (ART), Drug Safety, Bioanalysis and Regulatory Development.

Accelera Oncology represents a unique combination of product development experience from cytotoxics to molecular targeted therapeutics, gained over time as an R&D site of major pharmaceutical companies (Pharmacia, Pfizer), and in collaboration with the leading clinical oncology centers in Europe and the USA.

Accelera Oncology experts are available to assess the status of your oncology program, and to provide advice and input to optimize drug development strategies.
EXPERIENCE

RESULTS:

ACCELERA BIOLOGICS

An increasing number of biological agents are being developed as therapeutics, prompting the interest of many pharmaceutical and biotech companies in laboratory techniques and specific animal models.

At Accelera, our dedicated Analytical Biology unit focuses on bioanalysis and immunogenicity testing of different biological drug products, such as bioactive recombinant proteins/peptides, therapeutic monoclonal antibodies, as well as oligonucleotides and gene therapeutics, providing an extensive battery of state-of-the-art technologies and GLP-compliant services.

Our animal facility, which accommodates rodent and non-rodent animal species, including non-human primates combined with Accelera’s Toxicology, ADME and PK capabilities, allows the execution of several integrated studies (e.g. PK/PD, repeated toxicity studies with TK) and service packages (e.g. IND enabling pre-clinical studies) to support the development of new biotherapeutics.
Leading experts are working in Accelera to provide services and scientific advice in special technology areas, including:

- Preformulation
- Cardiovascular Safety Pharmacology
- Drug-drug interactions
- *In vitro* DART
- Infusion Technologies in NHP
- LC-MS/MS of proteins
- ELISA
- Electron Microscopy
- Immunohistochemistry
- Radiosynthesis
- QWBA
- PBPK and PK/PD Modelling
- Population PK